We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
+16.47%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$1.4B
AUM Growth
+$418M
Cap. Flow
+$336M
Cap. Flow %
23.99%
Top 10 Hldgs %
35.88%
Holding
162
New
35
Increased
43
Reduced
14
Closed
8

Top Buys

Rank Stock Value
1
ITOS
iTeos Therapeutics
ITOS
+$36.7M
2
CRBP icon
Corbus Pharmaceuticals
CRBP
+$30.7M
3
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$27.6M
4
RLAY icon
Relay Therapeutics
RLAY
+$26.7M
5
IMCR icon
Immunocore
IMCR
+$25.5M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$24.4M
2
DVAX
Dynavax Technologies
DVAX
+$6.61M
3
BEAM icon
Beam Therapeutics
BEAM
+$2.58M
4
CRSP icon
CRISPR Therapeutics
CRSP
+$2.54M
5
INBX icon
Inhibrx
INBX
+$2.37M

Sector Composition

Rank Sector Weight
1 Healthcare 95.59%
2 Technology 1.47%
3 Communication Services 1.22%
4 Real Estate 0.34%
5 Financials 0.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNS
51
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$8.27M 0.59%
4,700,000
-100,000
-2% -$140K
LQDA icon
52
Liquidia Corp
LQDA
$8.02B
$8M 0.57%
800,000
+450,000
+129% +$4.92M
DSGN icon
53
Design Therapeutics
DSGN
$876M
$7.97M 0.57%
1,480,975
– –
ALXO icon
54
ALX Oncology
ALXO
$290M
$7.65M 0.55%
+4,204,735
New +$15.6M
VKTX icon
55
Viking Therapeutics
VKTX
$4B
$7.6M 0.54%
120,000
– –
INSM icon
56
Insmed
INSM
$28.6B
$7.3M 0.52%
100,000
– –
DNTH icon
57
Dianthus Therapeutics
DNTH
$6.09B
$7.25M 0.52%
264,692
– –
BHVN icon
58
Biohaven
BHVN
$2.21B
$7M 0.5%
140,000
– –
BIIB icon
59
Biogen
BIIB
$30.7B
$6.78M 0.48%
35,000
– –
VTYX
60
DELISTED
Ventyx Biosciences
VTYX
$6.76M 0.48%
3,100,000
– –
BLCO icon
61
Bausch + Lomb
BLCO
$5.99B
$6.75M 0.48%
+350,000
New +$5.79M
CNTA
62
DELISTED
Centessa Pharmaceuticals
CNTA
$6.4M 0.46%
+400,000
New +$4.9M
GPCR icon
63
Structure Therapeutics
GPCR
$3.78B
$6.34M 0.45%
144,500
– –
BCRX icon
64
BioCryst Pharmaceuticals
BCRX
$2.4B
$6.08M 0.43%
800,000
– –
IONS icon
65
Ionis Pharmaceuticals
IONS
$9.4B
$6.01M 0.43%
150,000
– –
ABCL icon
66
AbCellera Biologics
ABCL
$2.12B
$5.98M 0.43%
2,300,000
+1,838,301
+398% +$5.09M
BDTX icon
67
Black Diamond Therapeutics
BDTX
$112M
$5.96M 0.43%
1,370,209
-232,991
-15% -$1.27M
APGE icon
68
Apogee Therapeutics
APGE
$10.2B
$5.87M 0.42%
100,000
– –
OMIC
69
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$5.83M 0.42%
+372,000
New +$3.31M
DTIL icon
70
Precision BioSciences
DTIL
$207M
$5.59M 0.4%
623,332
– –
LNTH icon
71
Lantheus
LNTH
$6.59B
$5.49M 0.39%
50,000
– –
CYTK icon
72
Cytokinetics
CYTK
$10.4B
$5.28M 0.38%
100,000
– –
NUVL
73
DELISTED
Nuvalent
NUVL
$5.12M 0.37%
+50,000
New +$4.15M
OKUR
74
OnKure Therapeutics
OKUR
$168M
$5.01M 0.36%
294,626
-5,000
-2% -$74K
MRUS
75
DELISTED
Merus
MRUS
$5M 0.36%
100,000
– –
1 2
3
4 5

Similar funds

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return

Tang Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Tang Capital Management held 162 positions worth $1.4B, up 43% from $982M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Tang Capital Management deployed $336M of net new capital in Q3 2024, opening 35 new positions and adding to 43 existing holdings. Its largest new stake was iTeos Therapeutics: 2,407,800 shares worth $24.6M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Dynavax Technologies, an estimated $6.61M trimmed.

  • Tang Capital Management's largest Q3 2024 buy was iTeos Therapeutics: 2,407,800 shares worth $24.6M.
  • Tang Capital Management added most to Aurinia Pharmaceuticals in Q3 2024, an estimated $27.6M increase.
  • Tang Capital Management's biggest Q3 2024 reduction was Dynavax Technologies, cutting an estimated $6.61M.
  • Tang Capital Management fully exited Eli Lilly in Q3 2024, selling an estimated $24.4M.
  • Tang Capital Management's ten largest holdings make up 36% of its $1.4B portfolio in Q3 2024.
  • Tang Capital Management opened 35 new positions and closed 8 in Q3 2024.
  • Tang Capital Management's portfolio value rose 43% quarter-over-quarter to $1.4B.

Based on Tang Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.